Navigation Links
Stress hormone may hasten the progression of certain blood cancers
Date:11/19/2007

COLUMBUS, Ohio Researchers here have shown that in cell cultures, the stress hormone norepinephrine appears to promote the biochemical signals that stimulate certain tumor cells to grow and spread.

The finding, if verified, may suggest a way of slowing the progression and spread of some cancers enough so that conventional chemotherapeutic treatments would have a better chance to work.

The study also showed that stress hormones may play a completely different role in cancer development than researchers had once thought.

The results appear in the current issue of the journal Brain, Behavior and Immunity.

We would not be surprised if we see similar effects of norepinephrine on tumor progression in several different forms of cancer, explained Eric Yang, first author of the paper and a research scientist with the Institute for Behavioral Medicine Research (IBMR) at Ohio State University.

Yang and colleague Ron Glaser, a professor of molecular virology, immunology and medical genetics, last year showed that the stress hormone norepinephrine was able to increase the production of proteins in cultures of nasopharyngeal carcinoma tumor cells that can foster the aggressive spread of the disease, a process known as metastasis. Glaser is director of the IBMR and a member of the Comprehensive Cancer Center at Ohio State.

In this latest study, the researchers looked at a different type of cancer multiple myeloma. One of several types of cancers of the blood, multiple myeloma strikes nearly 20,000 Americans each year, killing at least half that many annually. Patients diagnosed with this disease normally survive only three to four years with conventional treatments.

Yang and Glaser focused on three multiple myeloma tumor cell lines, each representing a different stage in the life of the disease, for their experiments. While all three tumor cell lines reacted to the presence of norepinephrine, only one, a cell line known as FLAM-76, responded strongly to the hormone.

The norepinephrine binds to receptors on the surface of the cells, sending a signal to the nucleus to produce a compound known as VEGF -- vascular endothelial growth factor that is key to the formation of new blood vessels, which the tumor must have to grow.

The FLAM-76 cell line was prepared from multiple myeloma tumor cells taken from a patient whose disease had not yet progressed too far from its original site in the bone marrow where blood cells are formed.

It turns out that FLAM-76 tumor cells more closely represent the earlier stages of the disease when blood vessel formation, a process called angiogenesis, is needed for disease progression, Yang said.

The fact that this one cell line, of the three multiple myeloma cell lines studied, closely represents the early stages of the tumor, and that this is where we see the biggest effect, is what makes this work more clinically relevant, Glaser said.

The researchers believe that blocking these receptors would slow the process of the growth of more blood vessel to the tumor, delaying disease progression and perhaps allowing treatments to be more effective. Widely used beta-blocker drugs now prescribed for high blood pressure work by blocking these same particular cell surface receptors, Yang said.

This approach wouldn't kill the tumor cells but it would diminish the blood supply to the tumor cells and slow them down, and that could translate into a longer and better quality of life for the patient, Glaser said.

The researchers and their colleagues are now working with other forms of cancer to test the effects of stress hormones like norepinephrine on their growth.

Glaser added that these kinds of results may change the way scientists are looking at a link between stress and the development and spread of cancer. In the past, he said, the focus was on how stress hormones weakened the immune system, allowing certain tumors to evade the body's defenses.

Now we have these stress hormones, not only affecting the immune response, but also acting directly on the tumor cells and inducing changes in the molecules made by those same tumor cells, Glaser said.

This has important implications for the spread of the tumor and metastasis.


'/>"/>

Contact: Eric Yang
yang.3@osu.edu
614-292-0364
Ohio State University
Source:Eurekalert

Related medicine news :

1. New research shows how chronic stress worsens neurodegenerative disease course
2. Ability to cope with stress can increase good cholesterol in older white men, study finds
3. Handling Stress Properly Increases Good Cholesterol
4. New Alzheimers findings: High stress and genetic risk factor lead to increased memory decline
5. Stressed-Out Moms Carry Babies on the Right
6. New Asthma Guidelines Stress Disease Control
7. Latest DES Analysis Stresses Importance of Physicians Well-Trained in Implantation Technique and Patient Follow-Up
8. Study identifies key player in the bodys immune response to chronic stress
9. Environmental stress probed in cardiovascular disease, diabetes
10. Parents PTSD May Boost Stress in Offspring
11. New nurses report job stress, need for better management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... ... and services, is proud to announce it has joined the National Association for ... the interests of chronically ill, disabled, and dying Americans of all ages and ...
(Date:3/28/2017)... ... March 28, 2017 , ... Via Oncology, ... the launch of a free, public-facing tool for analyzing the costs of various ... to provide comparative information to patients, providers, insurers and pharmaceutical companies about the ...
(Date:3/28/2017)... ... March 28, 2017 , ... Z-Medica, LLC, a ... Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) to equip ... in association with efforts by the American College of Surgeons, U.S. Department of ...
(Date:3/28/2017)... ... 28, 2017 , ... Usually, the impending arrival of warmer weather means the ... about a double chin, this means more anxiety than elation. The cosmetic dermatology experts ... people, a double chin is undesirable,” Dr. Goldman said, “but it seems doubly so ...
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, qualification, ... ensuring high-quality results and maintaining GMP and USP compliance. In a new webinar ... with GMP requirements " these requirements are explained. The challenge is to ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)...  Las Vegas ophthalmology practice, Center For Sight, announced ... Dublin ), an implant that shunts ... intraocular pressure in patients with moderate to severe glaucoma. ... glaucoma that can lead to progressive optic nerve damage ... untreated. According to the National Eye Institute, ...
(Date:3/28/2017)... 2017 The U.S. Food and Drug ... adults with moderate-to-severe eczema (atopic dermatitis). Dupixent is ... adequately by topical therapies, or those for whom ... used with or without topical corticosteroids. ... approving new and innovative therapies for patients with ...
(Date:3/28/2017)... , March 28, 2017  "US Cancer Generics ... the various indicators and trend analysis related to ... in mainstream pharmaceutical market in US. The report ... the growth on cancer generics drugs in recent ... saving of billions of dollars for various stake ...
Breaking Medicine Technology: